Dominari (DOMH) Competitors $3.63 +0.10 (+2.83%) As of 04/4/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. IRWD, SGMO, ACHV, RGLS, LXRX, FBIO, AGEN, CRIS, BOLT, and SABSShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Fortress Biotech (FBIO), Agenus (AGEN), Curis (CRIS), Bolt Biotherapeutics (BOLT), and SAB Biotherapeutics (SABS). These companies are all part of the "biotechnology" industry. Dominari vs. Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Regulus Therapeutics Lexicon Pharmaceuticals Fortress Biotech Agenus Curis Bolt Biotherapeutics SAB Biotherapeutics Ironwood Pharmaceuticals (NASDAQ:IRWD) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Does the MarketBeat Community favor IRWD or DOMH? Ironwood Pharmaceuticals received 514 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformIronwood PharmaceuticalsOutperform Votes51461.12% Underperform Votes32738.88% DominariN/AN/A Which has more volatility and risk, IRWD or DOMH? Ironwood Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Dominari has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Which has higher valuation and earnings, IRWD or DOMH? Dominari has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$351.41M0.61-$1.00B-$0.03-44.67Dominari$12.59M3.15-$22.88M-$3.87-0.94 Is IRWD or DOMH more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to Dominari's net margin of -180.22%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-0.65% -0.96% 0.74% Dominari -180.22%-32.89%-29.47% Do analysts prefer IRWD or DOMH? Ironwood Pharmaceuticals currently has a consensus price target of $8.60, indicating a potential upside of 541.79%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Ironwood Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer IRWD or DOMH? In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than Dominari. MarketBeat recorded 6 mentions for Ironwood Pharmaceuticals and 3 mentions for Dominari. Ironwood Pharmaceuticals' average media sentiment score of 0.41 beat Dominari's score of 0.18 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dominari 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of IRWD or DOMH? 42.5% of Dominari shares are owned by institutional investors. 12.9% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryIronwood Pharmaceuticals beats Dominari on 11 of the 17 factors compared between the two stocks. Remove Ads Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariSecurity brokers & dealers IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.61M$25.23B$5.26B$7.12BDividend YieldN/A2.52%4.89%4.06%P/E Ratio-0.9412.2221.2817.50Price / Sales3.154.57355.3285.42Price / CashN/A22.5238.1834.64Price / Book0.372.316.243.79Net Income-$22.88M$1.45B$3.21B$247.48M7 Day Performance-24.06%-10.91%-8.43%-6.76%1 Month Performance-52.11%-15.21%-4.83%-11.50%1 Year Performance15.61%11.47%2.57%-7.79% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari1.402 of 5 stars$3.63+2.8%N/A+29.2%$39.61M$12.59M-0.944Upcoming EarningsIRWDIronwood Pharmaceuticals3.6985 of 5 stars$1.49+5.7%$8.60+477.2%-83.6%$238.44M$351.41M-49.67220Gap DownSGMOSangamo Therapeutics1.4509 of 5 stars$0.87+0.4%$5.17+493.9%+14.2%$194.73M$57.80M-1.16480News CoverageGap UpACHVAchieve Life Sciences1.6612 of 5 stars$2.97+5.7%$15.75+430.3%-51.3%$103.01MN/A-2.6320Gap DownRGLSRegulus Therapeutics2.8819 of 5 stars$1.44+5.1%$15.00+941.7%-33.1%$95.39MN/A-1.3530LXRXLexicon Pharmaceuticals3.1218 of 5 stars$0.37+0.6%$3.67+903.5%-79.7%$89.98M$31.08M-0.49140Analyst ForecastShort Interest ↓Gap DownFBIOFortress Biotech2.4494 of 5 stars$1.72+0.6%$21.00+1,120.9%-18.7%$47.48M$62.50M-0.56170Earnings ReportAnalyst RevisionAGENAgenus3.0084 of 5 stars$1.64+1.9%$8.75+433.5%-84.6%$41.51M$103.46M-0.15440Gap DownCRISCuris2.2694 of 5 stars$2.60-2.3%$23.00+784.6%-92.3%$22.01M$10.26M-0.3360Earnings ReportAnalyst RevisionGap DownBOLTBolt Biotherapeutics3.3636 of 5 stars$0.44-0.3%$1.25+185.6%-72.9%$16.75M$9.78M-0.2690Positive NewsSABSSAB Biotherapeutics3.0189 of 5 stars$1.60-7.0%$12.40+675.0%-74.4%$14.77M$2.24M0.00140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Regulus Therapeutics Competitors Lexicon Pharmaceuticals Competitors Fortress Biotech Competitors Agenus Competitors Curis Competitors Bolt Biotherapeutics Competitors SAB Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
